Current Work - Gastrointestinal / Genitourinary 

SECOND APPEALS PERIOD

SEP 27, 2013 12:00 PM - OCT 28, 2013 6:00 PM 

No appeals were filed during this time. 

Measure 0659 

APPEALS PERIOD

AUG 16, 2013 9:00 AM - sep 16, 2013 6:00 PM 
 

No appeals were filed during this time.  

• Measure 0658  
• Measure 2065 

The NQF Board of Directors ratified two measures for gastrointestinal quality measures.
Announcement of Board Endorsement 

The Board endorsed an additional gastrointestinal quality measure, addressing colonoscopy screening rates in patients with a history of colonic polyps.
Announcement of Board Endorsement 

• Agenda (PDF) 
• CSAC Memo - Colonoscopy Quality Index Measure Review (PDF)
• CSAC Memo - Member Voting (PDF)
• CSAC Memo - Voting Results (PDF) 

• Draft Report (PDF)
• Voting Memo (PDF)
• Final Comments with Responses (XLSX)
• Sample Voting Ballot (PDF)

• Draft Report (PDF)
• Comments Received (XLSX) 

POST-COMMENT CONFERENCE CALL

JUN 10, 2013 4:00 PM - 6:00 PM 

• Agenda (PDF)
• Memo (PDF)
• Comments received and actions taken (XLSX)
• Meeting Transcript (PDF)
• Meeting Recording (MP3)

The Steering Committee met via conference call in March and April to evaluate the submissions and prepare the draft report.

Measures (PDFs): 

• 0098: Urinary Incontinence: Assessment, Characterization, and Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older – an administrative measure  
• 0622: Upper Gastrointestinal Study in Adults with Alarm Symptoms  
• 0635: Chronic liver disease - Hepatitis A vaccination  
• 0658: Endoscopy/polyp surveillance: Appropriate follow-up interval for normal colonoscopy (UPDATED 6/11)
• 0659: Endoscopy/Poly Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps- Avoidance of Inappropriate Use (UPDATED 6/11)
• 2056: Colonoscopy Quality Index  
• 2065: GI Hemorrhage Mortality Rate (IQI #18) 

NQF sought member comments on measures submitted to the project. Comments submitted by the deadline were considered by the Steering Committee during their evaluation of the measures.

Measures (PDFs): 

• 0098: Urinary Incontinence: Assessment, Characterization, and Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older – an administrative measure 
• 0622: Upper Gastrointestinal Study in Adults with Alarm Symptoms 
• 0635: Chronic liver disease - Hepatitis A vaccination 
• 0658: Endoscopy/polyp surveillance: Appropriate follow-up interval for normal colonoscopy 
• 0659: Endoscopy/Poly Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps- Avoidance of Inappropriate Use 
• 2056: Colonoscopy Quality Index 
• 2065: GI Hemorrhage Mortality Rate (IQI #18) 

Table of Member Comments (Excel)

Measure Developer Guidebook 

The Board of Directors ratified the 12 concepts that were approved by CSAC.

Stage 1 Final Report (PDF)

CSAC approved 12 of the 14 concepts recommended by the Steering Committee.

• Agenda (PDF)
• CSAC Memo (PDF)

Review the CSAC meetings.

• Draft Report (PDF)
• Letter of Reconsideration (PDF)
• Comments Received (Excel)

Comments Received (PDF)

Measures Submitted (PDFs):

• 0030: Urinary Incontinence Management in Older Adults - a. Discussing urinary incontinence, b. Receiving urinary incontinence treatment – A patient reported measure 
• 0098: Urinary Incontinence: Assessment, Characterization, and Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older – an administrative measure 
• 0622: Upper Gastrointestinal Study in Adults with Alarm Symptoms 
• 0635: Chronic Liver Disease - Hepatitis A Vaccination 
• 0658: Endoscopy/Polyp Surveillance: Appropriate follow-up interval for normal colonoscopy in average risk patients 
• 0659: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps-Avoidance of Inappropriate Use 
• C 2037: Objective characterization of pelvic organ prolapse prior to surgery 
• C 2038: Performing vaginal apical suspension (uterosacral, iliococygeus, sacrospinous or sacral colpopexy) at the time of hysterectomy to address uterovaginal prolapse 
• C 2049: Complete Workup for Assessment of Stress Urinary Incontinence Prior to Surgery 
• C 2050: Patient counseling on treatment options, including behavioral and surgical treatments prior to SUI surgery 
• C 2051: Patients Counseled About Risks Associated with the Use of Mesh in Sling Surgery Prior to Surgery 
• C 2052: Reduction of Complications through the use of Cystoscopy during Surgery for Stress Urinary Incontinence 
• C 2054: Assessment of treatment within one year of SUI surgery 
• C 2056: Quality Quest Request for Reconsideration 
• C 2059: IBD preventive care: corticosteroid sparing therapy 
• C 2062: IBD preventive care: corticosteroid related iatrogenic injury – bone loss assessment 
• C 2063: Use of cystoscopy concurrent with prolapse repair surgery 
• C 2065: Gastrointestinal Hemorrhage Mortality Rate (IQI #18) 

Submitted Concepts 

STEERING COMMITTEE MEETING

AUG 27, 2012 - AUG 28, 2012

• Agenda (PDF)
• Meeting Transcripts (PDFs): Day 1 | Day 2 

The Call for Measure Concepts closed on July 16.

• Call for Concepts (PDF)
• Guidance for Concept Submission & Review (PDF)